Pharma’s pricing troubles will get worse in 2017

The defining story of the past year in biopharma has been drug pricing, as much as the industry might wish otherwise. But though much of the anxiety has been over politically driven criticism and the potential for government price curbs, the only real pricing pressure in the U.S. has come from the private sector. Pharmacy…
To read the full story, Subscribe or
Subscribe to PBN
- Advertisement -